TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Major Shareholder Acquires $249,998.84 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) major shareholder Equity Ab Frankenius bought 62,972 shares of the company’s stock in a transaction dated Tuesday, December 17th. The stock was bought at an average cost of $3.97 per share, with a total value of $249,998.84. Following the completion of the transaction, the insider now owns 6,230,748 shares in the company, valued at approximately $24,736,069.56. This trade represents a 1.02 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

TriSalus Life Sciences Stock Down 4.3 %

NASDAQ:TLSI traded down $0.16 on Thursday, reaching $3.60. 40,022 shares of the company’s stock traded hands, compared to its average volume of 39,509. The firm has a market cap of $109.77 million, a PE ratio of -1.45 and a beta of 0.56. The stock has a 50-day simple moving average of $4.16 and a 200-day simple moving average of $4.97. TriSalus Life Sciences, Inc. has a 12 month low of $3.50 and a 12 month high of $10.42.

Analyst Upgrades and Downgrades

TLSI has been the topic of several recent research reports. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Cantor Fitzgerald started coverage on shares of TriSalus Life Sciences in a report on Tuesday. They set an “overweight” rating and a $10.00 target price for the company. Roth Mkm started coverage on TriSalus Life Sciences in a research report on Monday, November 11th. They set a “buy” rating and a $11.00 price objective for the company. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Finally, Oppenheimer initiated coverage on TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 target price for the company. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, TriSalus Life Sciences has an average rating of “Buy” and an average target price of $11.79.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Duquesne Family Office LLC lifted its holdings in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after buying an additional 110,966 shares in the last quarter. Highbridge Capital Management LLC bought a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at about $1,184,000. Geode Capital Management LLC grew its position in shares of TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares in the last quarter. Wolverine Asset Management LLC bought a new stake in shares of TriSalus Life Sciences in the second quarter worth about $240,000. Finally, MSD Partners L.P. purchased a new stake in shares of TriSalus Life Sciences in the third quarter worth about $184,000. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.